Text Size

Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00364793
First received: August 15, 2006
Last updated: June 18, 2012
Last verified: February 2012
History of Changes
  Purpose

The primary purpose of this study is to find the dose of Efavirenz for young children. The safety and how the medication is tolerated will also be studied.


Condition Intervention Phase
HIV Infections
 Drug: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Pharmacokinetics of EFV derived from plasma concentrations versus time. [ Time Frame: Week 24 and 48 analysis of PK assessments (Weeks 2, 10 and potentially one other time) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy as measured by the proportion of subjects with plasma HIV RNA levels <400 copies/mL and <50 copies/mL [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: No ]
  • Safety as measured by the frequency and severity of [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]
  • adverse events [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]
  • treatment-related adverse events [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]
  • serious adverse events [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]
  • discontinuation from study due to adverse events [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]
  • laboratory abnormalities [ Time Frame: Weeks 24 and 48 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 32
Study Start Date: February 2007
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)

Oral Solution, Capsules or Tablets, Oral, once daily

Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)

Didanosine (ddI) 240 mg/m2 (max 400 mg)

Emtricitabine (FTC) 6 mg/kg (max 200 mg)

Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);

Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)

Other Names:
  • Sustiva
  • BMS-561525

  Eligibility

Ages Eligible for Study:   3 Months to 6 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-1 infected; >=3 months of age to <=6 years of age (at time of treatment); screening plasma viral load >=1000 copies/mL

Exclusion Criteria:

  • Genotypic or phenotypic resistance to EFV, ddl, or FTC/3TC at screening
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00364793

Locations
Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina, 1245
Local Institution
Buenos Aires, Argentina, 1425
Colombia
Local Institution
Cali, Colombia
Mexico
Local Institution
Df, Distrito Federal, Mexico, 06720
Local Institution
Guadalajara, Jalisco, Mexico, 44280
Local Institution
Guadalajara, Jalisco, Mexico, 44160
Local Institution
Morelia, Michioacan, Mexico, 58000
Local Institution
Monterrey, Nuevo Leon, Mexico, 64460
Local Institution
Colima, Mexico, 28019
Local Institution
Puebla, Mexico, 72000
Local Institution
San Luis Potosi, Mexico, 78240
Panama
Local Institution
Ciudad De Panama, Panama, 0816-00383
South Africa
Local Institution
Bloemfontein, Free State, South Africa, 9301
Local Institution
Westdene, Gauteng, South Africa, 2092
Local Institution
Cape Town, Western Cape, South Africa, 7505
Thailand
Local Institution
Bangkok, Thailand, 10330
Local Institution
Bangkok, Thailand, 10700
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
BMS Clinical Trials Disclosure  This link exits the ClinicalTrials.gov site
Investigator Inquiry form  This link exits the ClinicalTrials.gov site
For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00364793     History of Changes
Other Study ID Numbers: AI266-922
Study First Received: August 15, 2006
Last Updated: June 18, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
HIV, Pediatric

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Didanosine
Efavirenz
 Emtricitabine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on May 16, 2013